Stay updated on OPUS Clinical Trial: Natalizumab in Focal Epilepsy
Sign up to get notified when there's something new on the OPUS Clinical Trial: Natalizumab in Focal Epilepsy page.

Latest updates to the OPUS Clinical Trial: Natalizumab in Focal Epilepsy page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has been updated to reflect a new version of a clinical study on natalizumab for drug-resistant focal epilepsy, including a revised study description and the removal of specific efficacy objectives and inclusion/exclusion criteria.SummaryDifference14%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to OPUS Clinical Trial: Natalizumab in Focal Epilepsy
Enter your email address, and we'll notify you when there's something new on the OPUS Clinical Trial: Natalizumab in Focal Epilepsy page.